Nexvet Biopharma (NVET) Inactive 10-Q2017 Q1 Quarterly report

Filed: 4 Nov 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adalimumab, analyzed, arrangement, beneficial, borrowing, brought, card, charge, collateral, Consumable, consumed, core, coupon, creation, CVB, delivery, detected, direct, employment, engineered, EPA, extinguishment, flow, freedom, frunevetmab, Humira, infliximab, insignificant, intangible, Keytruda, larger, long, lower, milestone, nivolumab, Opdivo, opposing, pembrolizumab, pharmacokinetic, piotal, portfolio, potency, predominance, preliminary, prepaid, prepayment, produce, produced, prominent, proportional, ready, Recoverability, recoverable, Remicade, Royalty, securitization, settlement, shelf, side, situation, software, solidify, steering, subsidiary, tangible, tolerated, undelivered, undiscounted, unrestricted, wide

Removed: acquirer, advancing, announced, arise, atopic, billing, blinded, cease, chronic, closing, coded, commencement, continuation, created, estimating, exchanged, experienced, formal, formed, fusion, goodwill, headcount, joining, line, listed, Memorandum, neural, NVET, NVIP, occurred, parent, partially, predecessor, proportionate, prospectively, provisional, rapidly, reduction, referred, reflected, rendered, reorganization, similarly, simplifying, symbol, Tevxen, treated, treatment, UK, ultimately

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

NVET similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12.1

STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

AND PREFERENCE SHARE DIVIDENDS

(in thousands)

		Three Months Ended September 30, 2016			Three Months Ended September 30, 2015
Earnings:
Net loss	$	(5,095	)	$	(3,9600	)
Add: Fixed charges		16			61
Earnings as defined	$	(5,079	)	$	(3,9544	)

Fixed charges:
Estimated interest component of rental expense (1)	$	26		$	61
Total fixed charges	$	26		$	61

Ratio of earnings to fixed charges (2)	$	—		$	—
Deficiency of earnings available to cover fixed charges	$	(5,079	)	$	(3,954	)
Combined fixed charges and preference share dividends:
Fixed charges	$	16		$	6
Preference share dividends		—			—
Total combined fixed charges and preference share dividends	$	16		$	6
Ratio of earnings to combined fixed charges and preference share dividends (2)	$	—		$	—
Deficiency of earnings available to cover combined fixed charges and preference share dividends	$	(5,079	)	$	(3,954	)

(1) One third of rental expense is estimated to be the interest component of rental expense.

(2) Earnings were insufficient to cover total fixed charges and total combined fixed charges and preference share dividends.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.